Prothena (NASDAQ:PRTA) Shares Pass Below Two Hundred Day Moving Average - Should You Sell?
Prothena (NASDAQ:PRTA) shares have fallen below their 200-day moving average, trading at $8.71 against the $9.37 average. Despite this, analysts maintain a "Moderate Buy" consensus with a $23.75 target price, and the company recently beat EPS and revenue expectations. Insider activity over the past 90 days shows net buying.
Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones
This article from Stock Traders Daily provides a detailed AI-driven analysis of Prothena Corporation Plc (PRTA), highlighting strong near-term sentiment but a neutral mid and long-term outlook. It outlines specific institutional trading strategies (Long, Momentum Breakout, and Risk Hedging) with entry/target/stop-loss zones, and presents multi-timeframe signal analysis including support and resistance levels. The analysis emphasizes risk management and predictive AI models for precision trading.
Precision Trading with Prothena Corporation Plc (PRTA) Risk Zones
This article provides a precision trading analysis for Prothena Corporation Plc (PRTA), highlighting a mid-channel oscillation pattern and a significant risk-reward short setup. It details three AI-generated institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss zones. The analysis also includes multi-timeframe signal analysis, noting strong near-term sentiment while mid and long-term outlooks are neutral.
Prothena files initial beneficial ownership statement for Todd W. Fennell
Prothena has filed an initial beneficial ownership statement (Form 3) for Todd W. Fennell, who is listed as a 10% owner. The filing, dated August 6, 2026, indicates that Fennell beneficially owns no securities, with no non-derivative or derivative holdings reported. The form was signed on August 11, 2026, by Reid E. Buchanan under power of attorney for Fennell.
HC Wainwright Issues Positive Estimate for Prothena Earnings
HC Wainwright has increased its FY2026 EPS estimate for Prothena to a loss of $0.47 per share, improving from a prior forecast of a $0.63 loss, while maintaining a "Buy" rating and a $30 price target. This positive adjustment follows Prothena's recent quarterly results, which surpassed expectations with an adjusted loss of $0.32 per share and revenue of $1.01 million. Analyst sentiment for Prothena remains largely positive, holding a consensus "Moderate Buy" rating and a $23.75 price target.
Prothena 10% owner William P. Scully buys $293,052 of common shares
William P. Scully, a 10% owner of Prothena, recently purchased 34,000 ordinary shares for $293,052, increasing his direct stake to 790,000 shares. Additionally, Manatee Equity Fund LLC, attributed to Scully, acquired 3,500 shares. Scully's spouse also holds 52,000 ordinary shares indirectly.
Renaissance Technologies LLC Has $5.91 Million Stock Position in Prothena Corporation plc $PRTA
Renaissance Technologies LLC increased its stake in Prothena Corporation plc (NASDAQ:PRTA) by 39.5% during the first quarter, now holding 607,515 shares valued at approximately $5.91 million. Institutional investors own 97.08% of the stock, while insiders have recently sold shares but also acquired a significant number of shares worth $3.10 million. Analysts maintain a "Moderate Buy" rating for Prothena, with an average price target of $23.75 compared to its recent share price of $8.49.
Prothena Corporation PLC (PRTA) Earnings Forecast: Future EPS & Revenue Growth Estimates
Prothena Corporation PLC (PRTA) has an earnings forecast score of 6.67, ranking 318th in the Biotechnology & Medical Research industry. Analysts have an average price target of $18.50 for PRTA, with expectations for the next quarter's revenue at $11.51M and EPS at -$0.24. The current analyst consensus is to "Hold" the stock.
Prothena (PRTA) Stock Shrugs Off Revenue Drop As Pipeline Stakes Rise
Prothena (PRTA) shares saw a modest 2.1% increase despite a significant drop in Q2 2026 collaboration revenue and a return to a net loss. Investors appear to be focused on the company's late-stage pipeline, including two Phase III programs, rather than recent financial results. The article highlights the tension between the stock's low price compared to its DCF estimate and ongoing losses, with both bullish and bearish arguments presented.
Prothena Corporation PLC (PRTA) Stock News Today
This article provides current stock information for Prothena Corporation PLC (PRTA), including its stock price, market capitalization, and a note that more news will be coming soon. It also lists various sections available on the TradingKey platform for PRTA, such as financials, stock score, and analyst ratings. The content primarily serves as a placeholder for future news and analysis related to the company.
Prothena Corporation plc (PRTA) stock price, news, quote and history
This Yahoo Finance page provides a comprehensive overview of Prothena Corporation plc (PRTA) stock, including its current price, historical data, and key financial metrics. It details the company's clinical-stage biotechnology pipeline, focusing on therapies for protein dysregulation diseases, and offers analyst insights and performance comparisons.
Prothena Reports Second Quarter 2026 Financial Results and Business Highlights
Prothena Corporation plc reported its second quarter and first six months 2026 financial results, highlighting a net cash used in operating and investing activities of $25.7 million for the quarter and a net cash provided of $3.2 million for the first six months. The company updated its year-end cash guidance to approximately $259 million (midpoint) and provided updates on its partnered clinical programs, including prasinezumab for Parkinson's disease, coramitug for ATTR amyloidosis with cardiomyopathy, and moponetug for Alzheimer's disease, which collectively represent up to $3 billion in future milestone payments. Prothena also detailed its active preclinical pipeline and financial performance, including a significant reduction in net loss compared to the previous year.
Prothena publishes corporate overview presentation on protein-dysregulation drug pipeline
Prothena has released a corporate overview detailing its protein-dysregulation drug pipeline, highlighting partnered late-stage programs such as Roche’s prasinezumab for Parkinson’s disease and Novo Nordisk’s coramitug for ATTR cardiomyopathy, both with primary completion expected in 2029. The company also noted a potential $55 million milestone from Bristol Myers Squibb-linked PRX019 and up to $105 million in clinical milestones by year-end 2026. Additionally, Prothena reported $22.3 million in share repurchases during the first half of 2026.
Prothena (PRTA) Reports Q2 Loss, Misses Revenue Estimates
Prothena (PRTA) reported a narrower-than-expected Q2 loss of $0.32 per share, beating the Zacks Consensus Estimate of a $0.39 loss. However, the company missed revenue estimates, posting $1.01 million against an expected $1.94 million, continuing a trend of missing revenue forecasts. Despite the earnings surprise, Prothena's stock has underperformed the S&P 500 year-to-date, and currently holds a Zacks Rank #3 (Hold).
Tranche Update on Prothena Corporation plc's Equity Buyback Plan announced on February 27, 2026.
Prothena Corporation plc has provided an update on its equity buyback plan, initially announced on February 27, 2026. Between April 1, 2026, and June 30, 2026, the company repurchased 1,454,898 shares for $14.98 million, representing 2.74% of its shares. This brings the total repurchased shares under the plan to 2,243,888, accounting for 4.21% of shares, at a total cost of $22.28 million.
FMR LLC discloses 13.8% Prothena (PRTA) ownership; key fund holds 6.4%
FMR LLC has disclosed a significant 13.8% beneficial ownership stake in Prothena Corporation plc (PRTA), holding 7,199,218 shares as of June 30, 2026. Abigail P. Johnson is noted with sole dispositive power over these shares, and the filing highlights that Fidelity Growth Company Commingled Pool holds 6.4% of Prothena's common stock, accounting for 3,335,877 shares. This SCHEDULE 13G/A filing indicates a passive investment purpose, with FMR LLC maintaining sole dispositive power but no shared voting power over its holdings.
Prothena Corporation PLC expected to post a loss of 39 cents a share - Earnings Preview
Prothena Corporation PLC is projected to report a loss of 39 cents per share in its upcoming earnings. This information is provided as an earnings preview by Refinitiv. The full article is available through a TradingView subscription.
Technical Reactions to PRTA Trends in Macro Strategies
This article provides a technical analysis of Prothena Corporation Plc (NASDAQ: PRTA) trends, highlighting weak near and mid-term sentiment and a neutral long-term outlook. It outlines three AI-generated institutional trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis also includes multi-timeframe signal strength, support, and resistance levels for various time horizons.
Prothena General Counsel Michael J. Isaacs disposes of common shares worth $111,080.17
Prothena General Counsel and Company Secretary Michael John Isaacs sold 13,080 ordinary shares in two transactions on July 28-29, totaling $111,080.17. The disposals reduced his beneficial ownership to 35,745 ordinary shares. This information was sourced from an original content publication by Prothena Corporation plc via EDGAR.
Press Release: Prothena to Report Second Quarter 2026 Financial Results on August 6
Prothena Corporation plc (PRTA) will announce its second quarter 2026 financial results on Thursday, August 6, 2026, before the market opens. Following the announcement, the company will host a conference call and webcast at 8:30 AM ET to discuss the results and provide a business update.
Prothena to Report Second Quarter 2026 Financial Results on August 6
Prothena Corporation plc announced it will report its second quarter and first six months of 2026 financial results on Thursday, August 6, 2026, after the U.S. financial markets close. The company, a late-stage clinical biotechnology firm, specializes in protein dysregulation with a pipeline targeting neurodegenerative and rare peripheral amyloid diseases. Prothena will not be holding a conference call for this financial results release.
Prothena Q2 Results: Financial data release set for Aug 6
Prothena Corporation plc is scheduled to release its Q2 and H1 2026 financial results on Thursday, August 6, 2026, after the close of U.S. financial markets. The biotech company, which specializes in protein dysregulation therapies for neurodegenerative diseases, will not hold a conference call in conjunction with the earnings release, consistent with its prior practices. This approach necessitates investors to review the written filing directly for performance metrics and insights without live analysis or management discussion.
Form 4 PROTHENA CORP PUBLIC LTD CO For: 30 July By Investing.com
This article reports on the filing of Form 4 for Prothena Corp Public Ltd Co on July 30, as published by Investing.com. Form 4 is a document that must be filed with the U.S. Securities and Exchange Commission (SEC) whenever there is a change in the beneficial ownership of a company's securities by insiders. The article includes general financial market data, but no specific details from the Prothena Corp filing.
PRTA|Prothena Corporation PLC|Price:8.090|Chg%:-0.320
This article provides a detailed financial overview and market analysis of Prothena Corporation PLC (PRTA). It highlights the company's strong fundamentals, high growth potential, and current valuation as fairly valued within the Biotechnology & Medical Research industry. The report also includes key insights such as high institutional ownership, analyst ratings, and technical indicators, suggesting a potential downward trend in the medium term despite strong fundamentals.
Prothena Corporation PLC (PRTA) Financial Health: Profitability & Balance Sheet Analysis
Prothena Corporation PLC (PRTA) has a robust financial score of 9.21, ranking 10th in the Biotechnology & Medical Research industry. The company demonstrated high operating efficiency with a 1706.36% year-over-year revenue increase and a 154.36% net profit increase in its latest quarter. Its financial health is considered strong across various metrics like Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns.
BlackRock (PRTA holder) discloses 6.9% beneficial stake in Prothena common stock
BlackRock, Inc. has filed an amended Schedule 13G, disclosing a 6.9% beneficial ownership stake in Prothena Corporation plc common stock. This translates to 3,587,480 shares, with BlackRock holding sole voting power over 3,533,090 shares and sole dispositive power over all 3,587,480 shares. The filing specifies that no single underlying BlackRock client owns more than 5% of Prothena's outstanding common shares.
Prothena Corporation PLC (PRTA) Valuation: PE, PB & Fair Value Analysis
The article provides a valuation analysis for Prothena Corporation PLC (PRTA), noting its current valuation score of 6.29 within the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -3.05, comparing it to recent highs and lows. The analysis also states that relevant data for P/B, P/S, and P/CF ratios have not yet been disclosed by the company.
Prothena Corporation PLC (PRTA) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of Prothena Corporation PLC (PRTA), identifying its major shareholders and their respective proportions, along with a breakdown by shareholder types. It also provides institutional shareholding data over several quarters, showing changes in shares held and proportion, and lists related ETFs that include PRTA.
Prothena Corp. Plc Revenue Breakdown – LSX:A1KAVV
This article provides a revenue breakdown for Prothena Corp. Plc (LSX:A1KAVV). Last year, the company generated 8.25 million EUR, predominantly from its "Collaboration" segment, which contributed 8.20 million EUR. The revenue was primarily sourced from the United States.
Prothena Corporation PLC (PRTA) Cash Flow
This article provides a comprehensive overview of Prothena Corporation PLC's (PRTA) cash flow statement, including detailed quarterly and annual data for operating, investing, and financing activities. It presents financial figures alongside year-over-year percentage changes, offering insight into the company's financial health and stability. The content also defines key cash flow metrics and answers frequently asked questions regarding PRTA's operating, investing, and free cash flow performance.
PRTA|Prothena Corporation PLC|Price:8.700|Chg%:-0.050
This article provides a detailed financial summary of Prothena Corporation PLC (PRTA), including its latest earnings report, income statement, balance sheet, and cash flow statement. It highlights key financial indicators such as EPS
Top Growth Companies With Insider Ownership For July 2026
This article identifies top growth companies in the United States with significant insider ownership, highlighting that high insider ownership aligns management's interests with shareholders. It provides a list of 10 such companies and then delves deeper into three examples: Kingstone Companies (KINS), Prothena (PRTA), and Equity Bancshares (EQBK), detailing their financials, growth forecasts, and insider activity. The article serves as a guide for investors seeking companies with both growth potential and strong internal confidence.
Prothena Corporation PLC (PRTA) Institutional Confidence
Prothena Corporation PLC (PRTA) has an institutional shareholding score of 10.00, placing it first in the Biotechnology & Medical Research industry. Institutional shareholding stands at 96.24%, an increase of 19.52% quarter-over-quarter. James Simons is the largest institutional shareholder, holding 1.14% of shares outstanding.
Prothena Corporation PLC (PRTA) Risk Assessment: Volatility, Financial Risk & Investment Risk
This article provides a risk assessment for Prothena Corporation PLC (PRTA), detailing its current risk score, beta value, and various volatility metrics. PRTA has a risk assessment score of 5.28, ranking 46 out of 386 in the Biotechnology & Medical Research industry, with a beta of -0.25 indicating it tends to underperform in up-markets but experiences smaller declines in down-markets. The report also highlights its maximum drawdown, Sharpe ratio, and daily return performance over different periods.
Prothena Corporation plc Revenue Breakdown – NASDAQ:PRTA
Prothena Corporation plc (NASDAQ: PRTA) generated $9.68 million USD in revenue last year. The majority of this, $9.63 million USD, came from its Collaboration segment, a decrease from $135.11 million USD the previous year. The United States was the company's primary revenue source.
Prothena stock trades steady as Alzheimer portfolio advances and earnings show growing R&D investmen
Prothena's stock reflects its focus on Alzheimer's and neurodegenerative diseases, with recent financial reports showing increased R&D spending and substantial cash reserves. While the company reported a net loss due to heavy R&D investment, its robust cash position of over $500 million provides a significant operating runway. The company's revenue is largely driven by volatile collaboration and milestone payments, highlighting its status as a clinical-stage biotech valued more for its pipeline potential than immediate profitability.
Trading the Move, Not the Narrative: (PRTA) Edition
Prothena Corporation Plc (NASDAQ: PRTA) is showing weak near and mid-term sentiment but maintains a strong long-term positive outlook. AI models have generated specific trading strategies with an exceptional 69.0:1 risk-reward setup, targeting a 16.4% gain against 0.2% risk. These strategies include position trading, momentum breakout, and risk hedging, all designed to optimize position sizing and minimize drawdown risk.
Trading the Move, Not the Narrative: (PRTA) Edition
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA), highlighting weak near-term sentiment but strong mid- and long-term outlooks, suggesting potential shifts. It details sophisticated AI-driven trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis to optimize trading decisions for various risk profiles. The report emphasizes an exceptional short setup with a 48.7:1 risk-reward ratio, targeting a 14.4% downside with minimal risk.
Prothena Corp plc updates investors on pipeline progress as neurodegeneration focus deepens
Prothena Corp plc, a clinical-stage biotechnology company, is updating investors on its pipeline progress in neurodegenerative diseases, particularly Alzheimer's and related disorders. The company specializes in developing therapies that target protein misfolding and is listed on Nasdaq, making it accessible to US investors. Prothena's strategy focuses on indications with high unmet medical need and aims to address the toxic effects of misfolded proteins in the brain.
Price to sales forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides a brief snapshot of the "Price to sales forward" for Prothena Corporation plc (NASDAQ: PRTA) as found on TradingView. It indicates that the market was closed at the time the data was accessed, and no trades were recorded for this specific metric. The content primarily points to the financial data offered by TradingView for PRTA.
AL Amyloidosis Pipeline 2026: Therapies Under Investigation, Clinical Trials Milestones, and FDA Approvals by DelveInsight | Sorrento Therapeutics, Prothena Therapeutics, Spectrum Pharma, Takeda
DelveInsight's "AL Amyloidosis Pipeline Insight, 2026" report details over 10 companies developing 10+ therapies for AL Amyloidosis, covering clinical trials, mechanisms of action, and FDA approvals. Key developments include orphan drug designation for Attralus, Inc.'s zamubafusp alfa, and Immix Biopharma's completion of patient enrollment for its Phase II NEXICART-2 trial, with topline data expected in Q3 2026. Prothena Corporation plc discontinued development of birtamimab after its Phase 3 trial failed to meet its primary endpoint, while Immix Biopharma received RMAT designation for NXC-201.
PRTA - Prothena Corp Plc Options
This article provides a detailed financial overview of Prothena Corp Plc (PRTA), including its stock performance, key financial metrics, and insider/institutional ownership data. It highlights the company's market capitalization, income, sales, and various valuation ratios, alongside its recent earnings performance and analyst recommendations. The data indicates recent price changes and performance over different periods.
Price to earnings forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides financial data, specifically the price-to-earnings forward ratio, for Prothena Corporation plc (NASDAQ:PRTA). It is a brief data point from TradingView's financial overview for the biotechnology company. The content appears to be a stub or a data lookup result rather than an analytical article.
(PRTA) Volatility Zones as Tactical Triggers
This article analyzes Prothena Corporation Plc (NASDAQ: PRTA) using AI models, highlighting strong sentiment across all horizons and identifying a mid-channel oscillation pattern. It presents three distinct trading strategies—Position, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional risk-reward short setup and offers multi-timeframe signal analysis to guide trading decisions.
Price to sales forward of Prothena Corp. Plc – MUN:0PT
This article displays the "Price to sales forward" metric for Prothena Corp. Plc (MUN:0PT). It presents the period, value, change, and change percentage for this financial indicator. The content largely consists of a placeholder table for financial data and navigation elements.
Price to book forward of Prothena Corporation plc – NASDAQ:PRTA
This page from TradingView provides financial information for Prothena Corporation plc (NASDAQ: PRTA). It specifically highlights the company's price to book forward metric, offering a snapshot of its financial valuation. The content focuses on market data and financial tools available on the platform for analyzing companies like Prothena.
Enterprise value to revenue forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides the enterprise value to revenue forward for Prothena Corporation plc (NASDAQ:PRTA). It lists the stock on the Nasdaq Stock Market and includes general information about its financial metrics. The original content appears to be a stub or a section of a larger financial data page on TradingView.
Enterprise value to EBIT forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBIT forward. It presents this metric in a table format, showing the period, value, change, and percentage change. The content appears to be a financial data snippet from a larger platform like TradingView.
Price to book forward of Prothena Corp. Plc – MUN:0PT
This article provides financial data for Prothena Corp. Plc (MUN:0PT), specifically focusing on its "Price to book forward" metric. The content highlights the company's financial overview on the Munich Stock Exchange, indicating market status and data source information.
Enterprise value to EBITDA forward of Prothena Corporation plc – NASDAQ:PRTA
This article provides current financial data for Prothena Corporation plc (NASDAQ: PRTA), specifically focusing on its enterprise value to EBITDA forward metric. The information is presented through TradingView, a financial platform offering various market tools and data. The page indicates that the market is closed and no trades have occurred for PRTA.
